## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Frederic Colland, et al.

Application No.: 10/520,712

Filed: December 22, 2005

For: Use of Specified TCF Target

Genes to Identify Drugs for the Treatment of Cancer, In Particular Colorectal Cancer, in which TCF/β-

Catenin/Wnt Signalling Plays a

Central Role

Examiner: Laura B. Goddard

Art Unit: 1642

Conf. No.: 2640

CERTIFICATE OF ELECTRONIC TRANSMISSION UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, including listed enclosures, is being electronically transmitted in Portable Document Form (PDF) through EFS-Web via Hyper Text Transfer Protocol in accordance with 1.6(a)(4) to the United

States Patent and Trademark Office on:

Dated:\_\_ Signed:\_

Jere Valles

## RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Sir:

This amendment is in response to the Office Action mailed March 25, 2008. A petition for a two-month extension of time and the required fee are being filed on or before June 25, 2008, making this a timely response. Although Applicants do not believe any additional fees are required, the Commissioner is hereby authorized to charge any such fees, including extension fees and additional claim fees, or credit any overpayment, to Deposit Account No. 50-0310 (Attorney Docket No. 067670-5005-US01).

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 10 of this paper.